Filtered By:
Specialty: Cardiology
Drug: Pradaxa

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 478 results found since Jan 2013.

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
CONCLUSION: Dabigatran, rivaroxaban, and apixaban appear to be superior to warfarin in both efficacy and safety in Asians with non-valvular AF.PMID:33968307 | PMC:PMC8069517 | DOI:10.4330/wjc.v13.i4.82
Source: World Journal of Cardiology - May 10, 2021 Category: Cardiology Authors: Wei-Jia Li Paraschos Archontakis-Barakakis Leonidas Palaiodimos Dimitrios Kalaitzoglou Lazaros Tzelves Apostolos Manolopoulos Yu-Chiang Wang Stefanos Giannopoulos Robert Faillace Damianos G Kokkinidis Source Type: research

Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation
Conclusion In this nationwide cohort study of patients ≥75 years initiating oral anticoagulation for AF, standard and reduced dose NOACs were associated with similar risks of stroke/SE as warfarin and lower or similar risks of bleeding. The NOACs seem to be a safe option also in elderly patients.
Source: Heart - February 16, 2022 Category: Cardiology Authors: Rutherford, O.-C. W., Jonasson, C., Ghanima, W., Söderdahl, F., Halvorsen, S. Tags: Open access Arrhythmias and sudden death Source Type: research

Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2
CONCLUSIONS: Dabigatran continues to be safe and well tolerated in patients with NVAF for stroke and systemic embolism prevention and continues to be prescribed appropriately. Treatment outcomes have not changed since the availability of idarucizumab. Since the J-Dabi1 study, treatment guidelines for anticoagulation use in NVAF have been updated based on emerging clinical evidence, accounting for differences in patient characteristics, and making dabigatran a preference for distinct patient populations.PMID:35717283 | DOI:10.1016/j.jjcc.2022.04.007
Source: Journal of Cardiology - June 18, 2022 Category: Cardiology Authors: Takeshi Yamashita Shinichiro Uchiyama Hirotsugu Atarashi Ken Okumura Yukihiro Koretsune Masahiro Yasaka Junichi Wakayama Taku Fukaya Hiroshi Inoue J-Dabigatran Surveillance Investigators Source Type: research

Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study
CONCLUSION: Among patients with AF and chronic liver disease, DOACs as a class were associated with lower risks of hospitalization for ischemic stroke/systemic embolism and major bleeding versus warfarin. However, the incidence of clinical outcomes among patients with AF and chronic liver disease varied between individual DOACs and warfarin, and in head-to-head DOAC comparisons.PMID:36762560 | DOI:10.1161/CIRCULATIONAHA.122.060687
Source: Circulation - February 10, 2023 Category: Cardiology Authors: Oluwadolapo D Lawal Herbert D Aronow Fisayomi Shobayo Anne L Hume Tracey H Taveira Kelly L Matson Yichi Zhang Xuerong Wen Source Type: research

Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
Conclusion Dabigatran is a cost-effective treatment in Sweden, as its incremental cost-effectiveness ratio is below the normally accepted willingness to pay limit.
Source: European Heart Journal - January 14, 2013 Category: Cardiology Authors: Davidson, T., Husberg, M., Janzon, M., Oldgren, J., Levin, L.-A. Tags: Arrhythmia/electrophysiology Source Type: research

Higher Persistence in Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran Versus Warfarin Original Articles
Conclusions— Patients who initiated dabigatran treatment were more persistent than patients who began warfarin treatment. Within each cohort, patients with lower stroke risk were more likely to discontinue therapy.
Source: Circulation: Cardiovascular Quality and Outcomes - September 17, 2013 Category: Cardiology Authors: Zalesak, M., Siu, K., Francis, K., Yu, C., Alvrtsyan, H., Rao, Y., Walker, D., Sander, S., Miyasato, G., Matchar, D., Sanchez, H. Tags: Compliance/Adherence, Other anticoagulants, Arrhythmias, clinical electrophysiology, drugs, Anticoagulants Original Articles Source Type: research

Dabigatran in Catheter Ablation of Atrial Fibrillation: A Call for a Randomized Control Trial
We read the study by Sardar et al entitled Meta-Analysis of Risk of Stroke or Transient Ischemic Attack With Dabigatran for Atrial Fibrillation Ablation. Sardar et al have conducted a rigorous systematic review and meta-analysis on the risk of stroke and transient ischemic attack with the use of dabigatran in catheter ablation (CA) of atrial fibrillation (AF) in comparison to warfarin. They have reported higher risk of thromboembolic events (including stroke and transient ischemic attack) with the periprocedural use of dabigatran contrary to several other meta-analyses that have shown no statistically significant differ...
Source: The American Journal of Cardiology - March 28, 2014 Category: Cardiology Authors: Aref A. Bin Abdulhak, Abdur Rahman Khan, Alan P. Wimmer Tags: Readers' Comments Source Type: research

Identifying Future Research Priorities Using Value of Information Analyses: Left Atrial Appendage Occlusion Devices in Atrial Fibrillation Health Services and Outcomes Research
Conclusion The relative efficacy of stroke reduction with left atrial appendage occlusion devices in relation to warfarin is an important source of uncertainty. Improving estimates of this parameter should be the priority for future research in this area.
Source: JAHA:Journal of the American Heart Association - September 16, 2014 Category: Cardiology Authors: Micieli, A., Bennell, M. C., Pham, B., Krahn, M., Singh, S. M., Wijeysundera, H. C. Tags: Health Services and Outcomes Research Source Type: research

Effectiveness and Safety of Dabigatran and Warfarin in Real-World US Patients With Non-Valvular Atrial Fibrillation: A Retrospective Cohort Study Health Services and Outcomes Research
Conclusions Dabigatran could be a safe and potentially more effective alternative to warfarin in patients with atrial fibrillation managed in routine practice settings.
Source: JAHA:Journal of the American Heart Association - April 10, 2015 Category: Cardiology Authors: Lauffenburger, J. C., Farley, J. F., Gehi, A. K., Rhoney, D. H., Brookhart, M. A., Fang, G. Tags: Health Services and Outcomes Research Source Type: research

Abstract 14: Clinical Characteristics and Treatment Patterns of Medicaid Patients with Atrial Fibrillation: Insights From the ORBIT-AF I Registry Session Title: Concurrent Session IIB: Oral Abstracts - Quality of Care
Conclusions: In a contemporary, community-based AF cohort, Medicaid patients had a greater comorbidity burden and higher stroke risk, yet were less likely to receive OAC compared with those with other forms of insurance.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: O'Brien, E. C., Kim, S., Thomas, L., Fonarow, G. C., Mahaffey, K. W., Kowey, P. R., Gersh, B. J., Burton, P. S., Piccini, J. P., Peterson, E. D. Tags: Session Title: Concurrent Session IIB: Oral Abstracts - Quality of Care Source Type: research

Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score.
CONCLUSIONS: Bleeding and stroke rates in Asian patients varied according to renal function and CHADS2score, but the relative benefits of DE over warfarin were preserved when analyzed by subcategories. PMID: 26248573 [PubMed - as supplied by publisher]
Source: Circulation Journal - August 6, 2015 Category: Cardiology Authors: Hori M, Fukaya T, Kleine E, Reilly PA, Ezekowitz MD, Connolly SJ, RE-LY Investigators Tags: Circ J Source Type: research

Dabigatran and apolipoprotein B
Dabigatran is the first of a series of new direct acting oral anticoagulants that was clinically introduced for the prevention of ischaemic stroke in patients with atrial fibrillation (AF). In the randomized evaluation of long-term anticoagulation therapy (RE-LY) study, dabigatran was shown to be superior or non-inferior to warfarin in preventing ischaemic stroke, depending on the dose administered (150 or 110 mg twice daily, respectively).1 This phase III trial opened the door to the clinical introduction of this direct thrombin inhibitor, resulting in a swift clinical uptake around the globe. This was rapidly follow...
Source: Heart - December 11, 2015 Category: Cardiology Authors: ten Cate, H. Tags: Drugs: cardiovascular system Editorials Source Type: research

Abstract 154: Estimating Treatment Effects in More Than Two Treatment Groups via Propensity Score Weighting: Practical Guidance and Application from Anticoagulant Therapy in Atrial Fibrillation Study Session Title: Abstract Poster Session I and Reception
Conclusions: Our results showed IPTW methods, correctly employed under certain assumptions, are practical and relatively simple tools to control for selection bias and other baseline differences in observational studies evaluating the comparative treatment effects of more than two treatment arms. When preserving sample size is important and in the presence of time-varying confounders, IPTW methods have distinct advantages over propensity matching or adjustment.
Source: Circulation: Cardiovascular Quality and Outcomes - February 26, 2016 Category: Cardiology Authors: Adeboyeje, G., Sylwestrzak, G., Barron, J. Tags: Session Title: Abstract Poster Session I and Reception Source Type: research